Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
14 Dec 2017 11:01 AM
RNS
Result of AGM
14 Dec 2017 07:00 AM
RNS
AGM Statement
20 Nov 2017 07:00 AM
RNS
Notice of AGM and Annual Report & Accounts
14 Nov 2017 12:05 PM
RNS
Placing
31 Oct 2017 07:00 AM
RNS
Sierra Reports Preclinical Data for Chk1 Inhibitor
19 Oct 2017 07:00 AM
RNS
Final Results
09 Oct 2017 12:00 PM
RNS
Sierra Oncology host KOL Meeting on 12 Oct in NY
18 Sep 2017 12:00 PM
RNS
Sierra Oncology to host call on Chk1 inhibitor
22 Aug 2017 07:00 AM
RNS
Pre-Close Trading Statement
19 Jun 2017 07:00 AM
RNS
Sareum to Present at the ICCS 2017
05 Jun 2017 12:13 PM
RNS
Chk1 Clinical Trials Update
31 May 2017 07:00 AM
RNS
Sierra Oncology Granted US and EU Patents
25 May 2017 07:00 AM
RNS
Sierra Oncology to Present at ASCO Annual Meeting
09 May 2017 07:00 AM
RNS
Sareum to Present at BioTrinity 2017
09 Mar 2017 07:00 AM
RNS
Director Shareholding
20 Feb 2017 07:00 AM
RNS
Half-year Results
09 Feb 2017 07:00 AM
RNS
Notice of Interim Results
09 Jan 2017 12:05 PM
RNS
Milestone Payment from Chk1 Licence Agreement
22 Dec 2016 09:47 AM
RNS
Result of General Meeting
15 Dec 2016 11:38 AM
RNS
Result of AGM
06 Dec 2016 07:00 AM
RNS
Directors' Remuneration & General Meeting
29 Nov 2016 07:00 AM
RNS
Sareum to Present at AACR-NCI-EORTC Conference
21 Nov 2016 07:00 AM
RNS
Notice of AGM
02 Nov 2016 07:00 AM
RNS
Final Results
24 Oct 2016 07:00 AM
RNS
Successful Outcome from TYK2 Feasibility Study
17 Oct 2016 07:00 AM
RNS
Japan and Singapore Patent Grants
27 Sep 2016 12:02 PM
RNS
Licence agreement for Chk1 Inhibitor CCT245737
03 Aug 2016 07:00 AM
RNS
China & HK Patent Grants for Sareum's Aurora+FLT3
28 Jul 2016 07:00 AM
RNS
Movement in share price
23 May 2016 12:00 PM
RNS
Clinical Trials CHK1 Inhibitor CCT245737 to Open
17 May 2016 07:00 AM
RNS
Change of Director
05 Apr 2016 10:38 AM
RNS
CHK1 Approved for Clinical Trials
24 Mar 2016 11:54 AM
RNS
Placing
14 Mar 2016 07:00 AM
RNS
Issue of Options
10 Mar 2016 12:55 PM
RNS
Share price movement
24 Feb 2016 07:01 AM
RNS
Research & Co-Development Collaborations Update
24 Feb 2016 07:00 AM
RNS
Half-Yearly Results for December 2015
01 Feb 2016 07:00 AM
RNS
CHK1 Clinical Trial Application Submissions
15 Dec 2015 11:20 AM
RNS
Result of AGM
15 Dec 2015 07:00 AM
RNS
CHK1 Clinical Trial Applications
13 Nov 2015 10:15 AM
RNS
Notice of AGM
26 Oct 2015 07:00 AM
RNS
Final Results
15 Sep 2015 07:00 AM
RNS
US and European Patent Grants for Aurora+FLT3
23 Jul 2015 07:00 AM
RNS
CHK1 Research Update
17 Jun 2015 07:00 AM
RNS
Funding Award from Innovate UK
28 May 2015 07:00 AM
RNS
Placing
21 May 2015 07:00 AM
RNS
Sareum Launches New Website
12 May 2015 07:01 AM
RNS
Sareum to Present at BioTrinity 2015
07 May 2015 07:00 AM
RNS
Early Conclusion of Equity Swap Agreement
16 Mar 2015 07:00 AM
RNS
Change of Adviser

Sareum Holdings Plc (Sareum) is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology, Sareum Kinase Inhibitor Library (SKIL). The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. Its research programs include Chk1 (checkpoint kinase 1), Aurora+FLT3 kinase, Autoimmune-TYK2/JAK1 kinases, and Cancer-TYK2/JAK1 kinases. Sareum's Chk1 kinase cancer research program is being conducted through joint research collaboration with Cancer Research Technology Limited and the Institute of Cancer Research. Sareum is headquartered in Cambridge, the UK.

SAR share price listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings